

# Utilizing Predictions of Early Prostate-Specific Antigen Selection for Adjuvant Systemic Therapy Trials

Journal of Clinical Oncology

18, 3240-3246

DOI: [10.1200/jco.2000.18.18.3240](https://doi.org/10.1200/jco.2000.18.18.3240)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Determinants of Prostate Cancer-Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4567-4573.	0.8	244
3	Diagnostic accuracy of prostate needle biopsy. <i>Current Urology Reports</i> , 2002, 3, 215-221.	1.0	5
4	The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 42, 179-188.	2.0	5
5	Variations Among Individual Surgeons in the Rate of Positive Surgical Margins in Radical Prostatectomy Specimens. <i>Journal of Urology</i> , 2003, 170, 2292-2295.	0.2	311
6	Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1376-1383.	3.0	475
7	The rationale for adjuvant chemotherapy for high-risk prostate cancer. <i>Current Opinion in Urology</i> , 2003, 13, 123-131.	0.9	2
8	Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy. <i>Cancer</i> , 2004, 101, 96-105.	2.0	49
9	PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPY. <i>Journal of Urology</i> , 2004, 172, S42-6; discussion S46-7.	0.2	125
10	Adjuvant Therapy in High Risk Prostate Cancer:. <i>European Urology Supplements</i> , 2004, 3, 43-50.	0.1	0
11	Positive Surgical Margins and Accessory Pudendal Artery Preservation During Laparoscopic Radical Prostatectomy. <i>European Urology</i> , 2005, 48, 786-792.	0.9	32
12	Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2005, 8, 353-358.	2.0	12
13	Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 8192-8197.	0.8	60
14	Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2005, 11, 4037-4043.	3.2	198
15	QUALITY IMPROVEMENT IN LAPAROSCOPIC RADICAL PROSTATECTOMY FOR pT2 PROSTATE CANCER: IMPACT OF VIDEO DOCUMENTATION REVIEW ON POSITIVE SURGICAL MARGIN. <i>Journal of Urology</i> , 2005, 173, 765-768.	0.2	59
16	Guidelines for primary radiotherapy of patients with prostate cancer. <i>Radiotherapy and Oncology</i> , 2006, 79, 259-269.	0.3	139
17	Nomograms for prostate cancer. <i>BJU International</i> , 2006, 98, 39-46.	1.3	58
18	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. <i>BJU International</i> , 2006, 98, 1204-1209.	1.3	62
19	Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 395-402.	0.4	36

#	ARTICLE	IF	CITATIONS
20	Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. <i>Journal of the National Cancer Institute</i> , 2006, 98, 715-717.	3.0	561
21	Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2007, 13, 5361-5367.	3.2	82
22	Surgical margin status of open versus laparoscopic radical prostatectomy specimens. <i>International Journal of Urology</i> , 2008, 15, 704-707.	0.5	26
23	Tumor Length in Prostate Cancer. <i>American Journal of Clinical Pathology</i> , 2008, 130, 77-82.	0.4	14
24	Prognostic Significance of Surgical Margin Status after Laparoscopic Radical Prostatectomy: Early Experience in a Single Institution in Japan. <i>Current Urology</i> , 2008, 2, 67-72.	0.4	0
25	Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. <i>BJU International</i> , 2009, 104, 315-320.	1.3	33
26	Predicting Post-External Beam Radiation Therapy PSA Relapse of Prostate Cancer Using Pretreatment MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 743-750.	0.4	36
27	Deletions of the Androgen-Metabolizing <i>UGT2B</i> Genes Have an Effect on Circulating Steroid Levels and Biochemical Recurrence after Radical Prostatectomy in Localized Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1550-E1557.	1.8	54
28	Synergistic Effects of the Green Tea Extract Epigallocatechin-3-gallate and Taxane in Eradication of Malignant Human Prostate Tumors. <i>Translational Oncology</i> , 2011, 4, 147-156.	1.7	77
29	Prognostic Factors for Failure after Prostatectomy. <i>Journal of Cancer</i> , 2011, 2, 1-19.	1.2	48
30	SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy. <i>European Urology</i> , 2011, 60, 1226-1234.	0.9	41
31	The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy. <i>European Urology</i> , 2012, 62, 88-96.	0.9	33
32	Positive margins after radical prostatectomy: Implications for failure and role of adjuvant treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 531-541.	0.8	17
33	Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. <i>Canadian Urological Association Journal</i> , 2013, 4, 13.	0.3	0
34	Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression. <i>BMC Medical Genetics</i> , 2014, 15, 143.	2.1	20
35	Prostate Cancer: Role of Pretreatment Multiparametric 3-T MRI in Predicting Biochemical Recurrence After Radical Prostatectomy. <i>American Journal of Roentgenology</i> , 2014, 202, W459-W465.	1.0	53
36	Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 331.e1-331.e7.	0.8	6
37	Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. <i>Scandinavian Journal of Urology</i> , 2016, 50, 255-259.	0.6	6

#	ARTICLE	IF	CITATIONS
38	Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 28-34.	2.0	13
39	Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy. <i>Prostate</i> , 2019, 79, 1793-1804.	1.2	15
41	Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management:evidentiary base. <i>Canadian Urological Association Journal</i> , 2010, 4, 13-25.	0.3	34
42	Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. <i>Reviews in Urology</i> , 2002, 4, 141-6.	0.9	0
43	Prognostic factors for failure after prostatectomy. <i>Journal of Cancer</i> , 2010, 2, 1-19.	1.2	24
44	Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6. <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 496-502.	0.5	7